Novartis Cuts 6 Early Cancer Candidates, Adds 2 to Refine Oncology Strategy

Why It Matters

The move sharpens Novartis' R&D focus, preserving capital for promising candidates while sustaining oncology’s revenue engine, crucial for long‑term competitive positioning.

Key Takeaways

• Novartis drops six Phase 1 oncology candidates.
• Adds two new Phase 1 assets: AMO959, GCJ904.
• Oncology sales grew 8% to $54.5 billion in 2025.
• Kisqali sales jumped 57% to $4.78 billion.
• Early‑stage deals focus under $2 billion valuations.

Pulse Analysis

Novartis' recent decision to retire six Phase 1 oncology projects while onboarding two fresh candidates underscores a disciplined approach to R&D portfolio management. The discontinued assets—KFA115, HRO761, MGY825, and AAA802—were all in early‑stage trials targeting solid tumors or prostate cancer. By pruning these programs, the company aims to reallocate resources toward higher‑potential molecules such as AMO959 for prostate cancer and GCJ904 for solid tumors. This move reflects a broader industry shift toward data‑driven go/no‑go decisions early in development.

On the commercial side, oncology remains Novartis' growth engine, delivering $54.5 billion in net sales and an 8% year‑on‑year increase in 2025. Flagship drugs like Kisqali and Scemblix posted double‑digit sales jumps, reinforcing the importance of a robust pipeline to sustain momentum. CEO Vas Narasimhan emphasized that early‑stage investments, often sourced through sub‑$2 billion deals, are critical for feeding the late‑stage pipeline and offsetting attrition risk. Competitors are similarly intensifying their hunt for breakthrough candidates, making strategic culling a competitive necessity.

Looking ahead, the two new Phase 1 assets could diversify Novartis' oncology portfolio and potentially unlock new revenue streams if they progress successfully through clinical milestones. Investors will watch the upcoming data readouts closely, as positive results could validate the company's selective R&D strategy and support its long‑term growth narrative. Moreover, the disciplined pruning may free capital for strategic acquisitions or collaborations, positioning Novartis to adapt swiftly to emerging therapeutic modalities such as radioligand therapies and bispecific antibodies.